تحميل...

Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria

BACKGROUND: Remission is the established goal in rheumatoid arthritis (RA) treatment. Although originally defined by a disease activity score in 28 joints (DAS28) <2.6, more stringent criteria may imply the absence of disease activity. The 2011 ACR/EULAR remission criteria provide the newest and...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Iking-Konert, Christof, Aringer, Martin, Wollenhaupt, Jürgen, Mosch, Thomas, Tuerk, Stefan, Feist, Eugen, Burmester, Gerd R
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BMJ Group 2011
الموضوعات:	Clinical and Epidemiological Research
الوصول للمادة أونلاين:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3184242/ https://ncbi.nlm.nih.gov/pubmed/21875873 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2011.152678
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria

مواد مشابهة